Form 4: Azitra CEO Francisco Salva Receives Stock Option Grant

Azitra, Inc. CEO Francisco D. Salva was granted 220,879 stock options as part of a standard equity compensation arrangement.

Summary

• Francisco D. Salva, President and CEO of Azitra, Inc., was granted 220,879 stock options on April 20, 2026.
• The options have an exercise price of $0.2127 per share.
• The options are set to expire on April 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company fundamentals.

Positives

• Aligns executive compensation with long-term shareholder value through equity-based incentives.

Negatives

• Results in potential future dilution for existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future performance of Azitra's common stock price relative to the $0.2127 exercise price.

Future Outlook

The options vest over a three-year period, with one-third vesting on the first anniversary of the grant and the remainder vesting in monthly installments thereafter, indicating a long-term retention strategy.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure leadership alignment with clinical and commercial milestones.

Comparison to Industry Standards

• The vesting schedule of one-third after one year followed by monthly vesting is consistent with standard industry practices for executive equity compensation.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on April 20, 2027.

Key Dates

Keywords

Azitra, AZTR, Form 4, Insider Trading, Stock Options, Executive Compensation